FDA fiscal year in review: New drug approvals in the wake of the pandemic and legislative reforms
AgencyIQ analyzed CDER’s novel drug approvals in Fiscal Year 2023, identifying a recovery in approval numbers as the agency resumes a new normal following the pandemic. AgencyIQ also uncovered some interesting trends for biologics and accelerated approvals that warrant consideration.

A quick note: How AgencyIQ gathers data on drug approvals

AgencyIQ reviews drug approvals from the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER).

Fill out the form to read the full article.